What does HRD status mean for Ovarian Cancer treatment

Understanding HRD Status in Ovarian Cancer Treatment

HRD stands for Homologous Recombination Deficiency — this is an important genetic characteristic of some ovarian cancers that significantly influences treatment decisions.

What HRD Status Tells Us

HRD status measures whether your cancer cells have problems with a specific DNA repair mechanism called "homologous recombination." Think of it this way: cancer cells, like all cells, have damage to their DNA that needs to be repaired. Homologous recombination is one of the cell's repair systems. When this system is defective (HRD-positive), cancer cells become vulnerable to certain targeted treatments.

HRD-positive means the cancer has this DNA repair deficiency — which is actually good news for treatment options.

HRD-negative (also called HRP, or Homologous Recombination Proficient) means the cancer cells have a functioning repair system — which limits the benefit of certain targeted drugs.

Why HRD Status Matters for Your Treatment

According to the NCCN Guidelines for Ovarian Cancer, HRD status is particularly important because it helps determine whether you'll benefit from PARP inhibitor (PARPi) therapy. PARP inhibitors are targeted drugs that work especially well in HRD-positive cancers.

Here's the clinical reasoning:

• If you have HRD-positive disease: PARP inhibitors (like olaparib, niraparib, or rucaparib) can be very effective because they exploit the cancer's existing DNA repair weakness
• If you have HRD-negative disease: The NCCN Guidelines note that PARP inhibitors are considered to have "minimal benefit" in these patients, so your doctor would likely recommend different treatment approaches

When HRD Testing is Recommended

According to NCCN Guidelines, HRD testing is recommended:

• For patients WITHOUT BRCA mutations — HRD status helps determine the magnitude of benefit from PARP inhibitor maintenance therapy
• For advanced stage disease — if you're being considered for PARP inhibitor therapy, HRD testing should be included in your molecular testing
• If not previously done — tumor molecular testing should be performed before starting therapy for persistent or recurrent disease

Questions to Ask Your Oncologist

Since HRD status directly impacts your treatment options, here are specific questions to discuss with your care team:

1. Has my tumor been tested for HRD status? If not, should it be?
2. What is my HRD status, and what does that mean for my specific treatment plan?
3. If I'm HRD-positive, am I a candidate for PARP inhibitor maintenance therapy?
4. If I'm HRD-negative, what alternative treatment approaches do you recommend?
5. How does my HRD status combined with my BRCA status (if known) influence the treatment options available to me?

Important Context

HRD status is one piece of your clinical picture. Your oncologist will also consider:

• Your BRCA mutation status (if tested)
• Your stage of disease
• Your prior treatments
• Your overall health and performance status
• Whether you have newly diagnosed or recurrent disease

The combination of all these factors — not HRD status alone — determines your personalized treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.